Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03422393
Title Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Michael Choi
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.